Health technology assessment (HTA) is a process, which should answer the question "Is a given health technology/medication worth its price for the value it provides " In the spirit of the amendments to the ? Bulgarian Health Insurance Act and institutionalization of HTA, our team prepared this situational evaluation aiming to throw light on the practices and approaches to in HTA European countries As a whole, we can identify two types . of agencies that perform it: those servicing the population of an entire nation or a region, and those working at the level of hospitals or a network of hospitals. All the agencies studied have two common characteristics. First, they were created with a non-profit purpose and second, all of them are financed by public funds in a variety of ways. It also becomes clear from the comparative analysis performed that the ways HTA is conducted in Europe differ from country to country. Irrespective of the variations, the common aspiration is that the value for a patient, to which the approved health technologies contribute, should be greater than the price to be paid for them. Bulgaria is may be the last EU state to implement HTA in its domestic legislation and this also gives the advantage of having and using the experience of the other countries. Establishing an independent structure, which is appointed to prepare local health technologies assessment would result in transparent decision-making, participation of all concerned parties and optimization of the budget for medicines regarding the effectiveness/benefit ratio, as well as expenses.
Introduction
Health technology assessment is a (HTA) multidisciplinary science whose role is, by detailed analyses, to study the medical, social, ethical and economic effects of the development, distribution and use of various . The health technologies [1] [2] [3] purpose of is to serve as bridge between the HTA world of science and the world of decision-making [4] . The process develops very rapidly worldwide and we see a rapid growth determined by the necessity of managerial, clinical and political decisions. The amplification of HTA is also due to the evolution of the methods of assessment in social and applied sciences, including clinical epidemiology and health economics. The decisions healthcare managers and politicians have to make become more and more important because the costs of wrong resolutions get higher and higher . [5] [6] [7] [8] [9] [10] Health technology assessment is a process, which should make judgments if a particular health technology/medication is worth its price for the value it provides. It is a more sophisticated type of 11 . In the pharmacoeconomic studies [ ] spirit of the amendments to the Bulgarian Health Insurance Act and the institutionalization of HTA, our team prepared this assessment, aiming at throwing a light on the practices and approaches to in European countries HTA .
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Types of HTA agencies
As a whole, we can identify two types of agencies: ones servicing the population of an entire nation or region national or regional ones , ( ) and others working at the level of healthcare institutions or a network of hospitals. The latter type facilitates the decisions of hospital management and the management of clinical activities The addresse s of national and . е regional agencies are the various management levels, at which decisions in the field of healthcare are made. On the one hand, the agencies aim at facilitating the process of decision-making at macro level, which affects large groups of people with health insurances with relevant funds. On the other hand, a part of the work of the agencies is directly related to the micro level in the process of making medical decisions at patient level, i.e. decisions made by clinicians when using a particular health technology. The users of the output data resulting , from the activity of the agency, may expect a different effect from its work and the dissemination of the data obtained is diverse [12] [13] [14] [15] [16] [17] [18] [19] .
Financing of the HTA agencies All studied agencies have two common characteristics. First, they were set up as nonprofit organizations. Second, all of them are supported by public funds and the ways of financing vary. The main source of financing is the budget for healthcare of each country. This is true for the health care systems financed directly from taxes, as well as for those, whose funding comes mainly from contributions of employers and contributions from individuals. Besides financing by the budgets for health care some , agencies receive additional resources from various public and private funds [20 21 ].
For example, " " é de Santé Haute Autorit (HAS) in rance is F subsidized by the government (10%). HAS also receives payment for accreditations performed contributions (15%), from health insurances fees from (31%), producers of medicinal products and (7%) revenues from the pharmaceutical industry (34%) which are in the form of tax on , e s promotional activities -.
[22 23] The financial resources of the HTA agencies in Europe vary from a little less than million 1 euros annually for most of the agencies, to more than million euros for the national agencies of 10 Holland, Great Britain, and in Germany IQWiG . Even after the relative share of the population serviced by a given agency has been taken into consideration, the range is still quite wide (US$ 0.02 US$ 0.89 ) to per capita of the population (T ) able 1 [24] . The variations in financing may be explained to some extent by the differences in the concepts for HTA In some countries, the assessments of . the agencies are mainly of the secondary type, usually a result of cooperation with experts from the academic field and clinicians in the capacity of consultants In other countries, the . H T A programs finance not only secondary assessments but also a big part of the primary studies, which have been considered significant for the relevant healthcare system.
Activities of the HTA agencies
Depending on the activities of the European HTA agencies, they may be classified into two categories. (Table 2) . AHTAPol
Norway
In Norway, the activities of the agency are even wider as a result of merging several functions. T h e N a s j o n a l t K u n n s k a p s s e n t e r f o r Helsetjenesten NOKC 2004 ( ) was established in by incorporation the former agency for of HTA-SMM, HELTEF -the foundation for scientific research in the field of health care, and the Scientific Department at the Ministry of Health and Social Policy.
is also responsible for NOKC monitoring the level of satisfaction of patients Djambazov S, Vekov T. Approaches for health technology assessment in europe: ...
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and healthcare professionals.
Germany
Gemeinsame Bundesausschuss -G-BA was founded in and is responsible for 2004 assessment of the technologies in both outpatient and inpatient health care that are reimbursed by the German system. In addition to SHI (Table 3) . decisions for reimbursement, G-BA is also accountable for issuing directives on the organizatin and quality assurance of the healthcare system. As a consultant in this activity, G-BA works with representatives of the social health insurance fund SHI), contractual partners ( from outpatient and inpatient healthcare, and independent consultants and representatives of patients' organizations.
The German Institute of Quality and Efficiency in Healthcare (Institut für Qualität und Wirtschaftlichkeit im GesundheitswesenIQWiG) performs assessments, including ones ordered by Nowadays produces G-BA.
, IQWiG HTA reports for medications, procedures, 
Conclusions
The comparative analysis presented in this paper shows that the ways of conducting in HTA Europe differ. Irrespective of the differences, the idea they share is that the value of approved health technologies for patients should be larger than the price to be paid. The health authorities in the various countries have found a modus operandi depending on the needs and expectations of society. At the same time, the development in the healthcare systems is very dynamic, i.e. evolution of the process of health technology assessment has not ended.
Bulgaria may be the last EU state to introduce HTA but this also may give the country the advantage of having the experience of the other countries, and use this experience.
The establishment of an independent structure, which can prepare local health technologies assessment, including data transfer and adaptation of practices of other countries, pre ration of manuals for HTA pa making reports and guidance for those structures [25] would , result in transparent decision-making, participation of all stakeholders and optimization of regarding costthe budget for medicines effectiveness ratio and expenses. 
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